Lin Huawei, Chang Jing, Li Jun
Department of Medicine, Shandong Medical College, Jinan 250002, P.R. China.
Department of Medical Oncology, The Third Affiliated Hospital, Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan 250031, P.R. China.
Iran J Public Health. 2020 Oct;49(10):1885-1893. doi: 10.18502/ijph.v49i10.4691.
To investigate the effects of docetaxel combined with icotinib on tumor markers in serum and quality of life of patients with advanced non-small cell lung cancer (NSCLC).
Overall, 121 patients with advanced NSCLC, admitted to the Third Affiliated Hospital of Shandong First Medical University, China from 2017-2018 were selected as subjects. Among them, 58 patients treated with docetaxel combined with icotinib for chemotherapy were considered as study group, and 63 patients treated with paclitaxel combined with carboplatin as control group. The clinical efficacy, adverse reactions, and ECOG scores of the two groups were observed. CEA, CA125, and SCC (Tumor markers) levels of the two groups before and after treatment were detected by chemiluminescence immunoassay (CLIA).
The leukopenia, oral mucosa ulcer and mild numbness in the control group were significantly higher than those in the study group (<0.05). After treatment, ECOG scores of both groups decreased (<0.05), and the ECOG score of the study group was significantly higher than that of the control group (<0.05). The serum CEA, CA125 and SCC levels of the study group and the control group after treatment decreased significantly compared with that before treatment (<0.05).
Application of docetaxel combined with icotinib for chemotherapy of patients with advanced NSCLC can effectively reduce the serum levels of CEA, SCC, and the CA125. Docetaxel combined with icotinib can significantly reduce adverse reactions and better improve the quality of life of patients compared with paclitaxel combined with carboplatin, which is worthy of clinical promotion.
探讨多西他赛联合埃克替尼对晚期非小细胞肺癌（NSCLC）患者血清肿瘤标志物及生活质量的影响。
选取2017年至2018年在中国山东第一医科大学第三附属医院收治的121例晚期NSCLC患者作为研究对象。其中，58例接受多西他赛联合埃克替尼化疗的患者作为研究组，63例接受紫杉醇联合卡铂化疗的患者作为对照组。观察两组的临床疗效、不良反应及美国东部肿瘤协作组（ECOG）评分。采用化学发光免疫分析法（CLIA）检测两组治疗前后癌胚抗原（CEA）、糖类抗原125（CA125）和鳞状细胞癌抗原（SCC，肿瘤标志物）水平。
对照组的白细胞减少、口腔黏膜溃疡及轻度麻木发生率显著高于研究组（<0.05）。治疗后，两组的ECOG评分均降低（<0.05），且研究组的ECOG评分显著高于对照组（<0.05）。研究组和对照组治疗后的血清CEA、CA125和SCC水平较治疗前均显著降低（<0.05）。
多西他赛联合埃克替尼应用于晚期NSCLC患者化疗可有效降低血清CEA、SCC和CA125水平。与紫杉醇联合卡铂相比，多西他赛联合埃克替尼可显著降低不良反应，更好地提高患者生活质量，值得临床推广。
